GLP-1 not stop for 1 week: GLP-1 not stop for 1 week
GLP-1 stop for 1 week: GLP-1 stop for 1 week
Study summary
This study aims to evaluate the impact of different discontinuation intervals of GLP-1 receptor agonists prior to colonoscopy on bowel preparation quality and the need for repeat colonoscopy, in order to establish appropriate discontinuation recommendations.
Eligibility
Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
* Inclusion Criteria for non GLP-1 user:
* Individuals who are scheduled to undergo total colonoscopy for any reasons
* Age between 18 to 70 years.
* ECOG Performance status is 0 or 1.
* Written consent to participate in the study has been obtained.
* Outpatient department patient
* Stop at least 3 days if current using medications that promote or inhibit gastrointestinal motility.
Exclusion Criteria:
* • Presence of severe comorbid conditions that preclude the safe performance of colonoscopy (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, chronic respiratory disease, or bleeding diathesis).
* History of prior gastric, small bowel, or colorectal segmental resection (patients with isolated appendectomy are eligible).
* Family history of hereditary colorectal cancer syndromes.
* Current or prior diagnosis of inflammatory bowel disease.
* Known colorectal polyposis syndromes.
* Any other condition deemed inappropriate for study participation at the discretion of the treating physician.
* Body mass index (BMI) \> 40 kg/m².
* Diagnosis of liver cirrhosis.
* Diagnosis of Parkinson's disease.
* Diagnosis of dementia.
* Use of tricyclic antidepressants or opioid medications for more than 3 months.
Primary outcome measure(s)
.Incomplete bowel preparation rate(IBP) through BBPS(Boston Bowel Preparation Scale) — "From enrollment to the end of Procedure and follow up for 30 days" Effect:
Primary outcome:
1.Incomplete bowel preparation rate(IBP) through BBPS(Boston Bowel Preparation Scale) (Total BBPS score \< = 5 or score \<= 1 in any segment)
Secondary outcomes:
1. Adenoma detection rate (ADR)
2. Detection rate number of advanced adenomas and colorectal serrated lesions
3. Time for scope insertion to cecum and withdrawal from the cecum to rectum.
4. Incidence of adverse events during colonoscopy
5. Weight gain or HSS was recorded after stopping GLP-1 and before colonoscopy
Trial sites (1)
Facility
City
Region
Status
FJUH
New Taipei
Taiwan
Recruiting
More Fu Jen Catholic University Hospital trials in Taiwan
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.